Testosterone and male contraception.
Level 5 - mechanism / opinion, no new human data
Narrative review without systematic methodology or primary data
PubMed 39155802 · doi:10.1097/MED.0000000000000880
What was done
This paper reviews the physiology, mechanisms, and current clinical development pipeline of reversible hormonal male contraceptives, focusing on androgen-only and androgen-progestin combinations like Nestorone/testosterone.
What was found
No quantitative data or clinical trial metrics are reported in the abstract. The authors describe the physiological mechanism whereby androgens and progestins suppress gonadotropins, lower intratesticular testosterone, and halt spermatogenesis while maintaining systemic eugonadism. They report that novel formulations, particularly Nestorone/testosterone, are preparing to enter pivotal Phase 3 trials.
Why it matters
Despite persistent demand and stagnant rates of unintended pregnancy, no reversible male hormonal contraceptive is currently marketed; this review summarizes the leading candidates approaching late-stage clinical evaluation.
Limits
As a narrative review, it presents no original clinical data, meta-analytic pooling, sample sizes, or quantitative safety and efficacy figures.
Cited by
- supports High levels of testosterone decrease sperm count and impair the immune system.